Results 91 to 100 of about 1,498,446 (168)

Medication improves velocity, reaction time, and movement time but not amplitude or error during memory-guided reaching in Parkinson's disease. [PDF]

Physiol Rep
Trevarrow MP, Munoz MJ, Rivera YM, Arora R, Drane QH, Pal GD, Verhagen Metman L, Goelz LC, Corcos DM, David FJ.   +9 more
europepmc   +1 more source

Gastroparesis in Parkinson's disease: Diagnostic and clinical implications for optimizing pharmacological treatment. [PDF]

J Parkinsons Dis
Damiens Q, Mille V, Faure J, Toussirot E, Valnet-Rabier MB, Béreau M.   +5 more
europepmc   +1 more source

Reflexive eye movement alterations are related to subclinical impulsive-compulsive behaviors in Parkinson's disease. [PDF]

Neurol Sci
Hapakova L, Straka I, Necpal J, Kusnirova A, Martis P, Valkovic P, Kosutzka Z.   +6 more
europepmc   +1 more source

LASSO logistic regression and cluster analysis in predicting adherence and drug patterns among new users of monotherapy for antihypertensive drugs. [PDF]

J Hypertens
Li X, Tia MD, Bos JHJ, Schuiling-Veninga CCM, Hak E, Mubarik S.   +5 more
europepmc   +1 more source

[Various kinds of antiparkinson agents and their characteristics].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003
Akiko, Nakatsuka, Masahiro, Nomoto
openaire   +1 more source

Reducing delays in time-critical medications for Parkinson's disease: a multifaceted, multiprofessional quality improvement project. [PDF]

BMJ Open Qual
Fisher J, Scott C.
europepmc   +1 more source

[More about antiparkinson agents].

Psychiatria polska, 1982
openaire   +1 more source

Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning. [PDF]

Basic Clin Pharmacol Toxicol
Pylkkö E, Courtois É, Paakinaho A, Hartikainen S, Kaasinen V, Elbaz A, Thiébaut ACM, Ahmed I, Tolppanen AM.   +8 more
europepmc   +1 more source

Factors associated with social functioning by relapse frequency in Japanese outpatients with schizophrenia: the Multicenter Treatment Survey and Assessments for Schizophrenia in Psychiatric Clinics (MUSASI). [PDF]

Psychol Med
Takekita Y, Katsumoto E, Adachi N, Kubota Y, Edagawa K, Azekawa T, Ueda H, Tamura T, Hongo S, Goto E, Hida H, Miki K, Fujii C, Watanabe K, Kato M, Yasui-Furukori N, Takeuchi H.   +16 more
europepmc   +1 more source

Chiral Analysis for High-Throughput Reaction Screening: Recent Advances in Accelerating Asymmetric Catalysis Discovery. [PDF]

Chemistry
Yu N, Zhao Y.
europepmc   +1 more source